ClinicalTrials.gg
CompletedNCT03628339Updated Jul 28, 2023Results posted

Effect of Tepotinib on PK of CYP3A Substrate Midazolam

A Phase 1 interventional study of Midazolam and Tepotinib in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 44 Years
Sex
All
01

Study summary

The study investigated the effect of tepotinib on the pharmacokinetics (PK) of the Cytochrome P450 (CYP) 3A substrate midazolam determined from concentrations of midazolam and its main metabolite 1-hydroxymidazolam in healthy participants.

02

Conditions studied

  • Healthy

Keywords

  • Tepotinib
  • Midazolam
  • Cytochrome P450
  • Pharmacokinetics
03

In context

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants of non-child bearing potential
  • Body weight between 50 to 100 kilogram (kg)
  • (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m\^2)
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participation in a clinical study within 60 days prior to first drug administration
  • Whole blood donation or loss of greater than 450 milliliter (mL) within 60 days prior to first drug administration
  • Any surgical or medical condition, or any other significant disease that could interfere with the study objectives, conduct, or evaluation
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Midazolam (Reference Treatment)

    Participants received single oral dose of 7.5 milligrams (mg) midazolam tablet on Day 1 of treatment period 1. The washout period between midazolam administrations in Period 1 and Period 2 was 12 days.

    Drug: Midazolam

  • Experimental
    Tepotinib + Midazolam (Test Treatment)

    All participants who received 7.5 mg midazolam tablet in treatment period 1 received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 along with 7.5 mg midazolam tablet on Day 11 in treatment period 2.

    Drug: Midazolam · Drug: Tepotinib

Interventions

  • Participant received single oral dose of 7.5 mg midazolam tablet on Day 1 of treatment period 1 and Day 11 in treatment period 2.

  • Participants received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 in treatment period 2.

06

What researchers measure

Primary outcomes

  1. Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam

    AUC0-t a Pharmacokinetic (PK) parameter was calculated according to the mixed log linear trapezoidal rule.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2

  2. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam

    AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2

  3. Maximum Observed Plasma Concentration (Cmax) of Midazolam

    Cmax was obtained directly from concentration versus time curve.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2

Secondary outcomes

  1. Time to Reach Maximum Plasma Concentration (Tmax) of Midazolam and Midazolam Metabolite (1-Hydroxymidazolam)

    Tmax is time to reach maximum observed plasma concentration obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2

  2. Elimination Half Life (t1/2) of Midazolam and Midazolam Metabolite (1-Hydroxymidazolam)

    Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2

  3. Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam Metabolite (1-Hydroxymidazolam)

    AUC0-t a Pharmacokinetic (PK) parameter was calculated according to the mixed log linear trapezoidal rule.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2

  4. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam Metabolite (1-Hydroxymidazolam)

    AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2

  5. Maximum Observed Plasma Concentration (Cmax) of Midazolam Metabolite (1-Hydroxymidazolam)

    Cmax was obtained directly from concentration versus time curve.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2

  6. Metabolic Ratio of Midazolam and Midazolam Metabolite (1-hydroxymidazolam)

    Metabolic ratio was calculated as AUC 0-infinity of midazolam divided by AUC 0-infinity of 1-hydroxymidazolam.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2

  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death

    Adverse event (AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign (including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event (SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs.

    Time frame: Baseline (Day 1 of treatment period 1) up to the End of Trial visit (Day 20)

  8. Number of Participants With Clinically Significant Changes in Laboratory Values

    Number of participants with clinically significant changes in laboratory values were reported. Clinical significance was decided by the investigator. Laboratory investigation included hematology and urinalysis.

    Time frame: From Screening up to the End of Trial visit (Day 20)

  9. Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)

    Number of participants with clinically significant changes in 12-lead ECG were reported. Clinical significance was decided by the investigator. The 12-lead ECGs were recorded after the participants have rested for at least 5 minute in supine position.

    Time frame: Day 1 (Treatment Period 1) up to the End of Trial visit (Day 20)

  10. Number of Participants With Clinically Significant Changes in Vital Signs

    Number of participants with clinically significant changes in vital signs were reported. Clinical significance was decided by Investigator. Vital signs included body temperature, blood pressure and pulse rate.

    Time frame: Day 1 (Treatment Period 1) up to the End of Trial visit (Day 20)

07

Results

Posted Jul 28, 2023

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Started120
Completed120
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Started012
Completed012
Not completed00

Outcome measures

PrimaryArea Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam

AUC0-t a Pharmacokinetic (PK) parameter was calculated according to the mixed log linear trapezoidal rule.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Reported as:
Geometric mean · hour*picogram per milliliter (h*pg/mL)
Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam
hour*picogram per milliliter (h*pg/mL)Midazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam107969 ± 42.0109477 ± 46.5
Statistical analysis
  • Midazolam (Reference Treatment) vs Tepotinib + Midazolam (Test Treatment) · % ratio of geometric least square mean: 101.40 · 90% CI 89.35 to 115.06
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam

AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Reported as:
Geometric mean · h*pg/mL
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam
h*pg/mLMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam109285 ± 41.9110550 ± 46.2
Statistical analysis
  • Midazolam (Reference Treatment) vs Tepotinib + Midazolam (Test Treatment) · % ratio of geometric least square mean: 101.16 · 90% CI 89.24 to 114.66
PrimaryMaximum Observed Plasma Concentration (Cmax) of Midazolam

Cmax was obtained directly from concentration versus time curve.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Reported as:
Geometric mean · pg/mL
Maximum Observed Plasma Concentration (Cmax) of Midazolam
pg/mLMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Maximum Observed Plasma Concentration (Cmax) of Midazolam49172 ± 59.750954 ± 54.1
Statistical analysis
  • Midazolam (Reference Treatment) vs Tepotinib + Midazolam (Test Treatment) · % ratio of geometric least square mean: 103.62 · 90% CI 86.91 to 123.56
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Midazolam and Midazolam Metabolite (1-Hydroxymidazolam)

Tmax is time to reach maximum observed plasma concentration obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Reported as:
Median · Hours
Time to Reach Maximum Plasma Concentration (Tmax) of Midazolam and Midazolam Metabolite (1-Hydroxymidazolam)
HoursMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Midazolam0.500 (0.500 to 1.50)0.508 (0.483 to 2.00)
Midazolam Metabolite (1- Hydroxymidazolam)0.500 (0.500 to 2.00)0.508 (0.483 to 2.00)
SecondaryElimination Half Life (t1/2) of Midazolam and Midazolam Metabolite (1-Hydroxymidazolam)

Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Reported as:
Geometric mean · Hours
Elimination Half Life (t1/2) of Midazolam and Midazolam Metabolite (1-Hydroxymidazolam)
HoursMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Midazolam5.52 ± 31.44.81 ± 41.2
Midazolam Metabolite (1- Hydroxymidazolam)6.34 ± 29.86.90 ± 26.8
SecondaryArea Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam Metabolite (1-Hydroxymidazolam)

AUC0-t a Pharmacokinetic (PK) parameter was calculated according to the mixed log linear trapezoidal rule.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Reported as:
Geometric mean · h*pg/mL
Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam Metabolite (1-Hydroxymidazolam)
h*pg/mLMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam Metabolite (1-Hydroxymidazolam)30589 ± 23.832627 ± 25.1
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam Metabolite (1-Hydroxymidazolam)

AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Reported as:
Geometric mean · h*pg/mL
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam Metabolite (1-Hydroxymidazolam)
h*pg/mLMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam Metabolite (1-Hydroxymidazolam)31269 ± 23.033372 ± 24.4
SecondaryMaximum Observed Plasma Concentration (Cmax) of Midazolam Metabolite (1-Hydroxymidazolam)

Cmax was obtained directly from concentration versus time curve.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Reported as:
Geometric mean · pg/mL
Maximum Observed Plasma Concentration (Cmax) of Midazolam Metabolite (1-Hydroxymidazolam)
pg/mLMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Maximum Observed Plasma Concentration (Cmax) of Midazolam Metabolite (1-Hydroxymidazolam)14909 ± 60.415852 ± 34.7
SecondaryMetabolic Ratio of Midazolam and Midazolam Metabolite (1-hydroxymidazolam)

Metabolic ratio was calculated as AUC 0-infinity of midazolam divided by AUC 0-infinity of 1-hydroxymidazolam.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Reported as:
Geometric mean · ratio
Metabolic Ratio of Midazolam and Midazolam Metabolite (1-hydroxymidazolam)
ratioMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Metabolic Ratio of Midazolam and Midazolam Metabolite (1-hydroxymidazolam)0.286 ± 37.20.302 ± 34.3
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death

Adverse event (AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign (including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event (SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs.

Time frame:
Baseline (Day 1 of treatment period 1) up to the End of Trial visit (Day 20)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death
ParticipantsMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
TEAEs110
Serious TEAEs00
TEAEs Leading to Death00
SecondaryNumber of Participants With Clinically Significant Changes in Laboratory Values

Number of participants with clinically significant changes in laboratory values were reported. Clinical significance was decided by the investigator. Laboratory investigation included hematology and urinalysis.

Time frame:
From Screening up to the End of Trial visit (Day 20)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Laboratory Values
ParticipantsMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Number of Participants With Clinically Significant Changes in Laboratory Values00
SecondaryNumber of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)

Number of participants with clinically significant changes in 12-lead ECG were reported. Clinical significance was decided by the investigator. The 12-lead ECGs were recorded after the participants have rested for at least 5 minute in supine position.

Time frame:
Day 1 (Treatment Period 1) up to the End of Trial visit (Day 20)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)
ParticipantsMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)00
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs

Number of participants with clinically significant changes in vital signs were reported. Clinical significance was decided by Investigator. Vital signs included body temperature, blood pressure and pulse rate.

Time frame:
Day 1 (Treatment Period 1) up to the End of Trial visit (Day 20)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
Number of Participants With Clinically Significant Changes in Vital Signs00

Adverse events

Collected over Baseline (Day 1 of treatment period 1) up to the End of Trial visit (Day 20). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Midazolam (Reference Treatment)0/12 (0%)0/12 (0%)1/12 (8.3%)
Tepotinib + Midazolam (Test Treatment)0/12 (0%)0/12 (0%)10/12 (83.3%)
Most frequent other events
Most frequent other events
EventMidazolam (Reference Treatment)Tepotinib + Midazolam (Test Treatment)
HeadacheNervous system disorders0/125/12
Abdominal pain upperGastrointestinal disorders0/124/12
DiarrheaGastrointestinal disorders0/124/12
Abdominal painGastrointestinal disorders0/122/12
Abdominal discomfortGastrointestinal disorders0/121/12
Abdominal pain lowerGastrointestinal disorders0/121/12
Gingival bleedingGastrointestinal disorders0/121/12
NauseaGastrointestinal disorders0/121/12
Medical device site reactionGeneral disorders1/120/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean35 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female0
Male12
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White10
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, 89231, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Oct 2018, 2 months.

Results were first posted in Jul 2023, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2018
First posted
Aug 14, 2018
StartActual
Aug 20, 2018
Primary completionActual
Oct 25, 2018
CompletionActual
Oct 30, 2018
Results first posted
Jul 28, 2023
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03628339
Responsible party
Sponsor
First posted
Aug 14, 2018
Start date
Aug 20, 2018
Primary completion
Oct 25, 2018
Completion
Oct 30, 2018
Results posted
Jul 28, 2023
Last update
Jul 28, 2023

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midazolam

Start the discussion